to patients

to bring scientific breakthroughs

Enabling innovative start-ups

About Curie Capital

Curie Capital, founded in 2018 and headquartered in Amsterdam, is a Life Sciences focused venture capital firm specialized in investing in early-stage companies. We have the experience, risk appetite and funds to invest in talented teams with exciting new medical products. We syndicate with experienced co-investors and support portfolio companies with our broad experiences in various areas and access to our extensive network. Curie Capital brings more to the table than capital; we actually help you to build your company.

We invest in Seed and Series A stage Biotechnology, Pharmaceutical and Medical Technology companies, typically focused on therapeutics, diagnostics or class IIb and III medical devices. From our current fund (Curie Capital 3), we are compliant with the RVO seed capital regulations and therefore invest only in companies that have a Dutch headquarters and that have, so far, not raised more than €3,5 million in equity and/or convertible loan agreements. With the start of our new fund, Curie Capital 4, expected 2024, we will invest in a broader scope of investment opportunities in high-impact Life Sciences companies within Europe.

The latest news

Stay informed about the latest updates from Curie Capital and the ongoing activities within our portfolio companies.

Our Team

We are a venture capital firm specializing in seed investments for innovative early-stage companies. Curie Capital typically takes on the role of lead investor. Our team comprises life science experts and business analysts who offer guidance to life science companies throughout the entire research and development process.

Han de Groot, MSc

Partner

Mariette van der Velden, MSc

Partner

Thom Frielink, MSc, MBA

Associate

Olivier Tak

Junior partner

Han de Groot, MSc

Partner

Mariette van der Velden, MSc

Partner

Thom Frielink, MSc, MBA

Associate

Olivier Tak

Junior partner

Our portfolio

We work closely with our portfolio companies to review transactions that leverage operational and management expertise.

“I am among those who find that science has great beauty” 
Dr. Marie Curie, winner of two Nobel Prizes (Physics and Chemistry)